Bradycardia is having a heart rate of <60 beats/minute that may not affect the hemodynamic status of some patients.
A heart rate that is
inadequate for the patient's current condition and may not be able to
support life is a clinically significant bradycardia.
Bradycardia can be caused by problems in the sinoatrial node, problems in the conduction pathways of the heart, metabolic problems or heart attack/disease that caused damage to the heart.
The different types of bradycardia are sinus bradycardia, sick sinus syndrome, tachycardia-bradycardia syndrome, hypersensitive carotid sinus syndrome, sinus pause/arrest, sinoatrial node exit block and atrioventricular block.
Combination therapy with ezetimibe/statin improved low-density lipoprotein (LDL) cholesterol levels and cardiovascular outcomes in patients with acute coronary syndrome (ACS), as stated in a 16-week one-centre, prospective, randomised, open-label clinical trial.
Prasugrel is superior than clopidogrel in the treatment of acute coronary syndrome (ACS) and ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) as presented in a study.
Earlier oral β blocker administration is substantially correlated with lower rates of left ventricular (LV) dysfunction and in-hospital mortality in acute coronary syndrome patients, according to a study.
The absence of the classical symptom of chest pain in patients with acute myocardial infarction (AMI) appears to be associated with more complications and higher short- and long-term mortality rates, particularly in younger and healthier patients, according to a study.